- Home
- GAMB vs ANTX Comparison
GAMB vs ANTX Comparison
Compare GAMB & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GAMB | ANTX |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | Jersey | United States |
| Employees | N/A | N/A |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.7M | 135.4M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | GAMB | ANTX |
|---|---|---|
| Price | $3.90 | $3.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $8.64 | $2.00 |
| AVG Volume (30 Days) | 574.4K | ★ 3.3M |
| Earning Date | 03-12-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $14.24 | N/A |
| Revenue Next Year | $11.26 | N/A |
| P/E Ratio | $89.96 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.77 | $1.00 |
| 52 Week High | $14.02 | $6.91 |
Technical Indicators
Market Signals| Indicator | GAMB | ANTX |
|---|---|---|
| Relative Strength Index (RSI) | 37.36 | 60.80 |
| Support Level | N/A | $1.05 |
| Resistance Level | $5.73 | $6.91 |
| Average True Range (ATR) | 0.24 | 0.90 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 18.57 | 49.70 |
Price Performance
Historical ComparisonAbout GAMB Gambling.com Group Limited
Gambling.com Group Ltd is a multi-award-winning performance marketing company and a provider of digital marketing services in the online gambling industry. Its principal focus is on online casinos online sports betting and the fantasy sports industry. It generates revenue by referring online gamblers to online gambling operators.
About ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.